There are 413 resources available
Invited Discussant 125MO and 126MO
Presenter: Carmen Criscitiello
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 2
Resources:
Webcast
171MO - Inflammatory profiling of individuals with germline TP53 mutations (gTP53m) and its relationship to subsequent cancer development
Presenter: Tarek BEN AHMED
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
95MO - Circulating tumor DNA (ctDNA) dynamics in patients (pts) receiving capecitabine (CAPE) for early-stage triple-negative breast cancer (eTNBC) with an incomplete response to neoadjuvant therapy (NAT)
Presenter: Tanya Gupta
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
4MO - Homologous recombination (HR) status of platinum responsive advanced triple negative breast cancers (aTNBC) treated with olaparib as maintenance therapy
Presenter: Tira Tan
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 171MO, 95MO and 3MO
Presenter: Andrew Tutt
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 2
Resources:
Webcast
Clinical impact of evolving ADC technology
Presenter: Heather McArthur
Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers
Resources:
Slides
Webcast
Current advances in breast cancer risk assessment: Prime time for a personalised approach?
Presenter: Antonis Antoniou
Session: From familial to theranostic germline genetics in breast cancer
Resources:
Slides
Webcast
Benefits of IO in early and metastatic breast cancer
Presenter: Isabel Pimentel
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Slides
Webcast